JP2007502791A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502791A5
JP2007502791A5 JP2006523579A JP2006523579A JP2007502791A5 JP 2007502791 A5 JP2007502791 A5 JP 2007502791A5 JP 2006523579 A JP2006523579 A JP 2006523579A JP 2006523579 A JP2006523579 A JP 2006523579A JP 2007502791 A5 JP2007502791 A5 JP 2007502791A5
Authority
JP
Japan
Prior art keywords
powder according
active substance
inhalable powder
surface area
specific surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006523579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502791A (ja
Filing date
Publication date
Priority claimed from DE10338407A external-priority patent/DE10338407A1/de
Application filed filed Critical
Publication of JP2007502791A publication Critical patent/JP2007502791A/ja
Publication of JP2007502791A5 publication Critical patent/JP2007502791A5/ja
Pending legal-status Critical Current

Links

JP2006523579A 2003-08-18 2004-08-12 Cgrpアンタゴニスト1−〔n2−〔3,5−ジブロモ−n−〔〔4−(3,4−ジヒドロ−2(1h)−オキソキナゾリン−3−イル)−1−ピペリジニル〕カルボニル〕−d−チロシル〕−l−リシル〕−4−(4−ピリジニル)−ピペラジンを含む新規吸入粉末製剤 Pending JP2007502791A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10338407A DE10338407A1 (de) 2003-08-18 2003-08-18 Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
PCT/EP2004/009017 WO2005018604A2 (de) 2003-08-18 2004-08-12 Neue inhalationspulver enthaltend den cgrp-antagonisten 1-[n2-[3,5-dibrom-n-[[4-(3,4-dihydro-2(1h)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazin

Publications (2)

Publication Number Publication Date
JP2007502791A JP2007502791A (ja) 2007-02-15
JP2007502791A5 true JP2007502791A5 (https=) 2007-09-27

Family

ID=34201783

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523579A Pending JP2007502791A (ja) 2003-08-18 2004-08-12 Cgrpアンタゴニスト1−〔n2−〔3,5−ジブロモ−n−〔〔4−(3,4−ジヒドロ−2(1h)−オキソキナゾリン−3−イル)−1−ピペリジニル〕カルボニル〕−d−チロシル〕−l−リシル〕−4−(4−ピリジニル)−ピペラジンを含む新規吸入粉末製剤

Country Status (5)

Country Link
EP (1) EP1663150A2 (https=)
JP (1) JP2007502791A (https=)
CA (1) CA2536050A1 (https=)
DE (1) DE10338407A1 (https=)
WO (1) WO2005018604A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
JPH0485063A (ja) * 1990-07-30 1992-03-18 Canon Inc 印刷装置
JPH0485064A (ja) * 1990-07-30 1992-03-18 Ricoh Co Ltd 両面プリンタ
AU2001230533A1 (en) * 2000-02-04 2001-08-14 Kissei Pharmaceutical Co. Ltd. Powdered preparation for inhalation and powder inhalant containing the same packed
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver

Similar Documents

Publication Publication Date Title
US11872314B2 (en) Pharmaceutical compositions
AU2014374552B2 (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin
JP2007502789A5 (https=)
KR20140075704A (ko) 오피오이드 작용제 및 오피오이드 길항제를 포함하는 변형억제 경구용 약제학적 용량형
JP6245677B2 (ja) 口腔内崩壊錠
JP2012036140A (ja) 苦味を抑制した速崩壊錠
EP2465495A1 (en) Tablet that disintegrates rapidly in the mouth and that contains two or more types of particles
JP4444626B2 (ja) 口腔内崩壊錠
JP4965130B2 (ja) 乾式直打速崩壊性錠剤
JP2007502791A5 (https=)
EP2717867A1 (en) Dry powder inhaler compositions comprising umeclidinium
EP2867199A2 (en) Stable compositions of fesoterodine
JP6112530B2 (ja) 安定化されてなる医薬組成物
JP7428836B2 (ja) 抗凝固薬の即時放出医薬製剤及びその調製方法
AU2016310340A1 (en) Pharmaceutical compositions comprising 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
JP6498158B2 (ja) 口腔内崩壊錠
JP2007502790A5 (https=)
RU2818086C2 (ru) Интраназальные фармацевтические порошковые композиции
JP2007502791A (ja) Cgrpアンタゴニスト1−〔n2−〔3,5−ジブロモ−n−〔〔4−(3,4−ジヒドロ−2(1h)−オキソキナゾリン−3−イル)−1−ピペリジニル〕カルボニル〕−d−チロシル〕−l−リシル〕−4−(4−ピリジニル)−ピペラジンを含む新規吸入粉末製剤
JP5928159B2 (ja) 医薬組成物
JP6982290B2 (ja) オンジエキス含有内服用固形医薬製剤
WO2025120308A1 (en) An orally disintegrating tablet of paroxetine and its process of preparation
BR112019002371B1 (pt) Composição farmacêutica intranasal em pó compreendendo partículas secas por aspersão, uso da referida composição para tratar ou prevenir dor de cabeça, dispositivo contendo a referida composição e método de preparo da referida composição farmacêutica
WO2025126137A1 (en) Pharmaceutical compositions of an a2a receptor antagonist
HUP0103459A2 (hu) (2S,3S,5R)-2-(3,5-difluorfenil)-3,5-dimetil-2-morfolinol tartalmú, orális adagolási formák hatékony mennyiségű stabilizáló alginsavval